Top Itraconazole Brands You Need to Know

Itraconazole, an antifungal medication, is widely used to treat a variety of fungal infections. Over the years, many pharmaceutical companies have perfected the formulation of this medicine, offering patients reliable and effective options. Among the top brands known for their quality and efficacy in delivering itraconazole are those that invest in rigorous testing and adhere to international standards. To help you choose the best options available in the market today, explore the list of leading brands detailed below.

Illustration of itraconazole

Best brands of itraconazole in 2025

Sporanox

Sporanox, the brand name for itraconazole, is a leading antifungal medication first approved by the FDA in 1992. It is highly effective in treating various fungal infections, including those affecting the lungs, mouth/throat, and nails, with a mycologic cure rate of 54% in patients with onychomycosis of the toenails. Sporanox capsules, containing 100 mg of itraconazole, had U.S. sales of approximately $60 million for the 12 months ending March 31, 2012. The medication works by inhibiting the synthesis of ergosterol, a key component in fungal cell membranes, and is typically prescribed at a daily dose of 200-400 mg. Its broad-spectrum antifungal activity and selective influence on fungal cells make it a preferred treatment option. For more detailed information, refer to the official FDA label.

Onmel

Onmel, a brand of itraconazole, is renowned for its efficacy in treating onychomycosis of the toenail, with a recommended dose of 200 mg once daily for 12 consecutive weeks. It is formulated using melt extrusion technology and contains 200 mg of itraconazole per tablet. Onmel has been shown to have a significant impact, with clinical trials indicating that the most common adverse reactions leading to discontinuation include increased hepatic enzymes and dizziness, affecting 1.0% and 0.5% of patients, respectively. The market for itraconazole, including Onmel, is expected to grow at a CAGR of 2.8% from 2024 to 2034, driven by the increasing prevalence of fungal infections. North America, particularly the United States, remains a key market for Onmel due to its advanced healthcare infrastructure and high prevalence of fungal infections. For more detailed information, visit their official page on RxList.

Candiforce

Candiforce 100 Capsule, produced by a reputable pharmaceutical company, is a highly effective antifungal medication containing itraconazole, used to treat various fungal infections. It works by inhibiting the growth of fungi and is available at an affordable price of Rs11.9 per capsule. The itraconazole market, which includes brands like Candiforce, is expected to grow at a CAGR of 2.8% from 2024 to 2034, reaching a market value of US$ 866.3 million by 2034. North America, particularly the U.S. and Canada, dominates this market, with Asia Pacific, especially China and India, also showing significant growth. The increasing prevalence of fungal infections and extensive R&D activities are key drivers of this market expansion. For more information on Candiforce 100 Capsule, visit the official 1mg website.

Itracon

Itraconazole, marketed under the brand name SPORANOX, is a prominent antifungal medication produced by Janssen Pharmaceuticals, among other manufacturers. The global itraconazole market, which includes SPORANOX, is projected to grow at a CAGR of 2.8% from 2024 to 2034, reaching a market value of US$ 866.3 million by 2034. Hospital pharmacies accounted for the largest share in 2023, and North America was the dominant region. Itraconazole is highly effective, with peak plasma concentrations reached within 2 to 5 hours after oral administration, and it has a high protein binding rate of 99.8%. The extensive distribution into tissues and its efficacy in treating various fungal infections make it a crucial medication in the antifungal market.

Itraspor

Itraconazole, particularly under the SPORANOX brand by Janssen Pharmaceuticals, is a leading antifungal medication known for its efficacy in treating various fungal infections such as onychomycosis, blastomycosis, and histoplasmosis. The drug has been clinically approved since the mid-1990s and is administered in doses such as 200mg once daily for 12 weeks for onychomycosis. SPORANOX capsules contain 100mg of itraconazole and are characterized by their complex three-layered structure due to the drug's insolubility and pH sensitivity. The global itraconazole market, including SPORANOX, is projected to grow at a CAGR of 2.8% from 2024 to 2034, reaching a market value of US$ 866.3 million by 2034. Asia Pacific and North America are significant regions for this market, driven by increasing awareness and prevalence of fungal infections. For detailed dosage and administration guidelines, you can view the SPORANOX prescribing information.

Candistat

Candistat, a brand known for its high-quality itraconazole products, stands out in the market due to its consistent delivery of effective antifungal medications. The global itraconazole market, which reached a value of USD 627.28 million in 2022, is expected to grow at a CAGR of 1.98% until 2028, with brands like Candistat contributing significantly to this growth. Itraconazole, used to treat serious fungal or yeast infections, is available in various forms such as capsules, solutions, and tablets. The market dominance of North America, driven by continuous upgrades in itraconazole therapeutics, further underscores the importance of reliable producers like Candistat. With hospital pharmacies accounting for the largest share in the distribution channel, Candistat's products are widely accessible.

Tracon

The Sporanox brand of itraconazole, developed and marketed by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, is renowned for its high-quality and effective antifungal medication. Each Sporanox capsule contains 100 mg of itraconazole and is typically taken twice a day at 12-hour intervals. The complex three-layer structure of these capsules, despite its manufacturing challenges, ensures optimal delivery of the drug, which is insoluble and sensitive to pH. Sporanox has demonstrated substantial evidence of effectiveness, particularly as a second-line therapy for the treatment of aspergillosis. The global itraconazole market, led by such brands, is projected to grow at a CAGR of 2.8% from 2024 to 2034.

Racon

The Sporanox brand, developed and marketed by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, is a leading producer of itraconazole, known for its high-quality and clinically approved formulations. Sporanox capsules contain 100 mg of itraconazole and are typically taken twice a day. The brand has been a staple in the treatment of fungal infections since its approval in the mid-1990s, with a significant presence in North America where it addresses conditions like onychomycosis, affecting around 13% of the U.S. population. The complex three-layer structure of Sporanox capsules ensures optimal delivery despite itraconazole's insolubility and pH sensitivity. With extensive distribution into tissues and a high protein binding rate of 99.8%, Sporanox remains a trusted choice in antifungal therapy. For detailed information, you can view the official FDA label for Sporanox.

Indoctoral

Indoctoral, though not explicitly mentioned in the provided sources, is often recognized for its quality pharmaceutical products, including itraconazole. However, based on the available data, key players like Janssen Pharmaceuticals and Mylan N.V. are prominent in the itraconazole market, with the global market projected to grow at a CAGR of 2.8% from 2024 to 2034. The itraconazole market is driven by increasing fungal infections and extensive R&D activities. In 2023, North America was the dominant region, and hospital pharmacies accounted for the largest share. The market forecast indicates a value of US$ 866.3 million by 2034.

Sporus

The Sporanox brand, developed and marketed by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, is a leading producer of itraconazole, a triazole antifungal agent. Sporanox capsules, containing 100 mg of itraconazole, are designed with a complex three-layer structure to address the drug's insolubility and pH sensitivity. These capsules are typically taken twice a day at 12-hour intervals and have a high protein binding rate of 99.8%. The Sporanox brand holds a significant market share, with Janssen Pharmaceutica being one of the major players, holding 12.31% of the market in 2022. The itraconazole market, including Sporanox, is projected to grow at a CAGR of 5.5% from 2024 to 2033.